UA117097C2 - Антитіло проти лігандів рецептора в1 брадикініну - Google Patents

Антитіло проти лігандів рецептора в1 брадикініну

Info

Publication number
UA117097C2
UA117097C2 UAA201411667A UAA201411667A UA117097C2 UA 117097 C2 UA117097 C2 UA 117097C2 UA A201411667 A UAA201411667 A UA A201411667A UA A201411667 A UAA201411667 A UA A201411667A UA 117097 C2 UA117097 C2 UA 117097C2
Authority
UA
Ukraine
Prior art keywords
antibody
des
badycinine
calidin
kallidine
Prior art date
Application number
UAA201411667A
Other languages
English (en)
Ukrainian (uk)
Inventor
Хань Лі
Доротеа Комінос
Цзе ЧЖАН
Алла Прітскер
Меттью Девісон
Ніколя Борен
Говіндан Субраманіан
Сінь Чень
Original Assignee
Санофі
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117097(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофі filed Critical Санофі
Publication of UA117097C2 publication Critical patent/UA117097C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201411667A 2012-03-28 2013-03-15 Антитіло проти лігандів рецептора в1 брадикініну UA117097C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04
PCT/US2013/031836 WO2013148296A1 (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Publications (1)

Publication Number Publication Date
UA117097C2 true UA117097C2 (uk) 2018-06-25

Family

ID=49261064

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201411667A UA117097C2 (uk) 2012-03-28 2013-03-15 Антитіло проти лігандів рецептора в1 брадикініну

Country Status (38)

Country Link
US (5) US9376494B2 (enExample)
EP (2) EP3246339B1 (enExample)
JP (5) JP6779012B2 (enExample)
KR (4) KR102035882B1 (enExample)
CN (3) CN104334578B (enExample)
AR (1) AR090352A1 (enExample)
AU (2) AU2013240242B2 (enExample)
BR (1) BR112014024282A2 (enExample)
CA (1) CA2868353C (enExample)
CL (2) CL2014002590A1 (enExample)
CO (1) CO7111293A2 (enExample)
CR (1) CR20140440A (enExample)
CY (1) CY1121466T1 (enExample)
DK (2) DK2831113T3 (enExample)
DO (1) DOP2014000199A (enExample)
EA (1) EA201491784A1 (enExample)
ES (1) ES2673869T3 (enExample)
GT (1) GT201400192A (enExample)
HR (1) HRP20180928T1 (enExample)
HU (1) HUE037720T2 (enExample)
IL (1) IL234830B (enExample)
LT (1) LT2831113T (enExample)
MA (1) MA37407B1 (enExample)
MX (2) MX361874B (enExample)
MY (2) MY166157A (enExample)
NZ (1) NZ631543A (enExample)
PE (1) PE20142170A1 (enExample)
PH (1) PH12014501970A1 (enExample)
PL (1) PL2831113T3 (enExample)
PT (1) PT2831113T (enExample)
RS (1) RS57413B1 (enExample)
SG (2) SG11201405162YA (enExample)
SI (1) SI2831113T1 (enExample)
TR (1) TR201808486T4 (enExample)
TW (1) TWI605060B (enExample)
UA (1) UA117097C2 (enExample)
UY (1) UY34682A (enExample)
WO (1) WO2013148296A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334578B (zh) * 2012-03-28 2021-10-08 赛诺菲 缓激肽b1受体配体的抗体
PE20152004A1 (es) 2013-03-13 2016-02-07 Prothena Biosciences Ltd Inmunoterapia tau
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
EP3390439B1 (en) 2015-12-15 2025-03-12 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809331RA (en) 2016-05-02 2018-11-29 Prothena Biosciences Ltd Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
PE20190261A1 (es) 2016-05-02 2019-02-25 Prothena Biosciences Ltd Anticuerpos que reconocen tau
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
IL270375B2 (en) 2017-05-02 2024-12-01 Prothena Biosciences Ltd Antibodies recognizing tau
KR102844399B1 (ko) * 2017-05-08 2025-08-11 아디맵 엘엘씨 항-cd3-결합 도메인 및 이를 포함하는 항체, 및 이를 생성하고 사용하는 방법
TW201945026A (zh) * 2018-01-29 2019-12-01 美商希拉諾斯醫療公司 結合erfe之抗體及使用方法
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN119306824B (zh) * 2024-10-08 2025-09-26 江苏埃尔迪生物科技有限公司 一种全价展示scFv的通用型M13噬菌体探针及其构建方法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
JP4768439B2 (ja) 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
JP2008504002A (ja) 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
KR100863776B1 (ko) 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP2008543810A (ja) 2005-06-14 2008-12-04 サイトス バイオテクノロジー アーゲー 抗原コンジュゲート及びその使用
US8460364B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
JP2010509920A (ja) * 2006-11-15 2010-04-02 メダレックス インコーポレーティッド Ｂｔｌａに対するヒトモノクローナル抗体および使用方法
WO2008151204A1 (en) 2007-06-04 2008-12-11 Sequent Medical Inc. Methods and devices for treatment of vascular defects
CN101820911B (zh) * 2007-06-12 2015-05-06 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
KR20140117638A (ko) 2007-08-29 2014-10-07 사노피 인간화된 항-ｃｘｃｒ5 항체, 이의 유도체 및 이들의 용도
DK2224954T3 (en) * 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
CN104334578B (zh) * 2012-03-28 2021-10-08 赛诺菲 缓激肽b1受体配体的抗体

Also Published As

Publication number Publication date
TW201343671A (zh) 2013-11-01
RS57413B1 (sr) 2018-09-28
CN104334578B (zh) 2021-10-08
US9376494B2 (en) 2016-06-28
MY184037A (en) 2021-03-17
AR090352A1 (es) 2014-11-05
DK3246339T3 (da) 2020-01-27
CA2868353A1 (en) 2013-10-03
EP3246339B1 (en) 2019-10-09
CN113773385A (zh) 2021-12-10
HK1206754A1 (en) 2016-01-15
PE20142170A1 (es) 2015-01-07
CN104334578A (zh) 2015-02-04
US20200115441A1 (en) 2020-04-16
KR102035882B1 (ko) 2019-10-24
EP3246339A1 (en) 2017-11-22
CY1121466T1 (el) 2020-05-29
HUE037720T2 (hu) 2018-09-28
CN120441698A (zh) 2025-08-08
US9879079B2 (en) 2018-01-30
MA37407A1 (fr) 2016-05-31
JP6912441B2 (ja) 2021-08-04
MA37407B1 (fr) 2018-03-30
AU2018203081A1 (en) 2018-05-24
TWI605060B (zh) 2017-11-11
CL2017003039A1 (es) 2018-03-16
JP2019050822A (ja) 2019-04-04
US20160368976A1 (en) 2016-12-22
LT2831113T (lt) 2018-06-25
MX361874B (es) 2018-12-18
PL2831113T3 (pl) 2018-08-31
JP2015513903A (ja) 2015-05-18
KR20220031728A (ko) 2022-03-11
PT2831113T (pt) 2018-06-20
MY166157A (en) 2018-06-06
KR102166083B1 (ko) 2020-10-16
KR102367723B1 (ko) 2022-02-28
DOP2014000199A (es) 2014-10-31
WO2013148296A1 (en) 2013-10-03
KR20150002679A (ko) 2015-01-07
CR20140440A (es) 2014-11-17
TR201808486T4 (tr) 2018-07-23
CN113773385B (zh) 2025-09-12
SI2831113T1 (en) 2018-08-31
HRP20180928T1 (hr) 2018-07-27
CO7111293A2 (es) 2014-11-10
EA201491784A1 (ru) 2015-02-27
JP2025134874A (ja) 2025-09-17
CL2014002590A1 (es) 2015-01-16
GT201400192A (es) 2015-07-29
JP7411609B2 (ja) 2024-01-11
ES2673869T3 (es) 2018-06-26
EP2831113A1 (en) 2015-02-04
US20230399388A1 (en) 2023-12-14
BR112014024282A2 (pt) 2017-08-08
SG10201702396QA (en) 2017-04-27
NZ631543A (en) 2017-03-31
JP2024038036A (ja) 2024-03-19
SG11201405162YA (en) 2014-09-26
JP6779012B2 (ja) 2020-11-04
JP2021166538A (ja) 2021-10-21
KR20200121370A (ko) 2020-10-23
EP2831113B1 (en) 2018-03-14
DK2831113T3 (en) 2018-06-25
PH12014501970A1 (en) 2014-11-17
CA2868353C (en) 2023-10-31
KR20190121861A (ko) 2019-10-28
US20180222967A1 (en) 2018-08-09
IL234830B (en) 2018-11-29
MX2014011688A (es) 2015-01-22
UY34682A (es) 2013-10-31
AU2013240242A1 (en) 2014-10-02
MX2018015914A (es) 2021-12-08
AU2013240242B2 (en) 2018-02-08
US20150050270A1 (en) 2015-02-19
US10465002B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
UA117097C2 (uk) Антитіло проти лігандів рецептора в1 брадикініну
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
NZ630363A (en) Anti-kit antibodies and uses thereof
UA115540C2 (uk) Антитіло до il-36r
CL2013003552A1 (es) Anticuerpo aislado que se une a la proteina 3 humana de tipo angiopoyetina (hangptl3); molécula de ácido nucleico; vector de expresión, célula hospedera; método de producción de un anticuerpo.
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201400875A1 (ru) Антитела к cd47 и способы их применения
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
UA116766C2 (uk) Зв'язувальна молекула, яка є біоспецифічною до вcma і cd3
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX369148B (es) Agentes de unión kir3dl2.
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
NI201400019A (es) Anticuerpo anti-alfabetatcr
EA201590412A1 (ru) Композиции антител и их применения
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
UA120047C2 (uk) Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r)